http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-078461-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_faf0f68bc9b66c444a1b7b970ce248f7 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4035 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-407 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-212 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-0804 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| filingDate | 2010-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eac147eb3c70029138e785d70945a261 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7d49e9047491656f08e514597aec8b0f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83e3abafb3106182a433f45a16e3cb02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_22268beaf5613fdd2d08f269bf2ce3fe http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70161b7a411f673fd1115e55956872b6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e2776aafb493ee27850e40b2750cc11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0372c832225beb7ba27d3e61e19a869d |
| publicationDate | 2011-11-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-078461-A1 |
| titleOfInvention | MACROCICLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION |
| abstract | The present additionally provides methods of treatment, which includes the methods for the treatment of an infection with the hepatitis C virus and the methods for the treatment of hepatic fibrosis, methods which generally involve the administration to an individual who This is required by an effective amount of a compound or composition of the present application. Claim 1: A compound is claimed which is governed by the structure of the formula (1), or a pharmaceutically acceptable salt or prodrug thereof, wherein W1, W2, W3 and W4 independently represent -D or -H, provided that at least one of W1, W2, W3 and W4 is -D; R1 is selected from the group consisting of -C (O) OR1e, optionally substituted heteroaryl and aryl optionally substituted with one or more substituents, each independently selected from the group consisting of halo, amino, C1-6 alkyl optionally substituted with up to 5 fluorescent, C1-6 alkoxy optionally substituted with up to 5 fluorescent, C2-6 alkenyl, C2-6 alkynyl, -C (O) NR1aR1b, -NHC (O) NR1aR1b, -C (O) OR1c and heteroaryl; R1e is selected from the group consisting of t-butyl, cycloalkyl and heterocyclyl; R1a and R1b are taken together with the nitrogen to which they are attached and form a piperazinyl or morpholinyl, each optionally substituted with one or more substituents independently selected from C1-6 alkyl, C2-6 alkenyl, C2- alkynyl 6, C (O) OR1c, -C (O) R1d, optionally substituted aryl and optionally substituted heteroaryl; R1c and R1d are each independently selected from the group consisting of -H, C1-4 alkoxy, C1-6 alkyl, C3-7 cycloalkyl, aryl, arylalkyl and heteroaryl; R3 is -OH, -NHS (O) 2R3a, -NHS (O) 2OR3a or -NHS (O) 2NR3bR3c; wherein R3a is selected from the group consisting of C1-6 alkyl, - (CH2) q3-7 cycloalkyl, - (CH2) q6 or C6 aryl and a heteroaryl, each optionally substituted with one or more substituents, each independently selected from the group consisting of halo, cyano, nitro, hydroxy, -COOH, - (CH2) C3-7 t-cycloalkyl, C2-6 alkenyl, hydroxy C1-6 alkyl, C1-6 alkyl optionally substituted with up to 5 fluorescent and C1-6 alkoxy optionally substituted with up to 5 fluorescent; where each of R3b and R3c independently represents a hydrogen atom or is independently selected from the group consisting of C1-6 alkyl, - (CH2) q3-7 cycloalkyl and C6 or 10 aryl, each optionally substituted with one or more substituents and each independently selected from the group consisting of halo, cyano, nitro, hydroxy, - (CH2) C3-7 t-cycloalkyl, C2-6 alkenyl, hydroxyC 1-6 alkyl, phenyl , C1-6 alkyl substituted with up to 5 fluores and C1-6 alkoxy substituted with up to 5 fluores; or R3b and R3c, taken together with the nitrogen to which they are attached, form a three to six membered heterocyclic ring coupled to the base structure through a nitrogen and the heterocyclic ring is optionally substituted with one or more substituents, each independently selected from the group consisting of halo, cyano, nitro, C1-6 alkyl, C1-6 alkoxy and phenyl; each t independently represents 0, 1 or 2; each q independently represents 0, 1 or 2; and any link represented by a continuous and dotted line represents a link selected from the group consisting of a single link and a double link. |
| priorityDate | 2009-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 36.